



Certificate of Analysis

www.tocris.com

Product Name: GW 5074 Catalog No.: 1381 Batch No.: 3

CAS Number: 220904-83-6

IUPAC Name: 3-(3,5-Dibromo-4-hydroxy-benzylidene)-5-iodo-1,3-dihydro-indol-2-one

1. PHYSICAL AND CHEMICAL PROPERTIES

Batch Molecular Formula: C₁₅H₈Br₂INO₂

Batch Molecular Weight: 520.94

Physical Appearance: Yellow solid

Solubility: ethanol to 1 mM

DMSO to 100 mM

Storage: Desiccate at -20°C

Batch Molecular Structure:

2. ANALYTICAL DATA

TLC: $R_f = 0.43$ (Dichloromethane:Methanol [95:5])

Melting Point:Between 267 - 268°CHPLC:Shows 96.9% purity

¹H NMR: Consistent with structure

Microanalysis: Carbon Hydrogen Nitrogen

Theoretical 34.58 1.55 2.69 Found 34.5 1.41 2.73

Caution - Not Fully Tested • Research Use Only • Not For Human or Veterinary Use



Product Information

Print Date: Jun 3rd 2025

www.tocris.com

Product Name: GW 5074 Catalog No.: 1381 Batch No.: 3

CAS Number: 220904-83-6

IUPAC Name: 3-(3,5-Dibromo-4-hydroxy-benzylidene)-5-iodo-1,3-dihydro-indol-2-one

Description:

GW 5074 is a potent, selective and cell-permeable c-Raf1 kinase inhibitor (IC $_{50}$ = 9 nM). GW 5074 displays \geq 100-fold selectivity for raf kinase over CDK1, CDK2, c-src, ERK2, MEK, p38, Tie2, VEGFR2 and c-fm. GW 5074 binds mutant huntingtin (mHTT) and decreases levels of mHTT in cultured hippocampal neurons and fibroblasts from patients with Huntington's disease. Brain penetrant.

Physical and Chemical Properties:

Batch Molecular Formula: $C_{15}H_8Br_2INO_2$

Batch Molecular Weight: 520.94 Physical Appearance: Yellow solid

Minimum Purity: ≥95%

Batch Molecular Structure:

Storage: Desiccate at -20°C

CAUTION - This product is light sensitive and we recommend that the solid material and any solutions obtained are protected from exposure to light.

Solubility & Usage Info:

ethanol to 1 mM DMSO to 100 mM

Stability and Solubility Advice:

Some solutions can be difficult to obtain and can be encouraged by rapid stirring, sonication or gentle warming (in a 45-60°C water bath).

Information concerning product stability, particularly in solution, has rarely been reported and in most cases we can only offer a general guide. *Unless contradicted by product-specific protocols or instructions, our standard recommendations apply:

SOLIDS: Provided storage is as stated on the product label and the vial is kept tightly sealed, the product can be stored for up to 6 months from date of receipt.

SOLUTIONS: We recommend that stock solutions, once prepared, are stored aliquoted in tightly sealed vials at -20°C or below and used within 1 month. Wherever possible solutions should be made up and used on the same day.

Licensing Information:

Sold for research purposes under agreement from Glaxo Wellcome Inc and Glaxo Group Ltd.

References:

Xue *et al* (2023) Discovery of a drug-like, natural product-inspired DCAF11 ligand chemotype. Nat.Commun. *14* 7908. PMID: 38036533. Li *et al* (2019) Allele-selective lowering of mutant HTT protein by HTT-LC3 linker compounds. Nature *575* 203. PMID: 31666698.

Chen *et al* (2008) Inhibition of ATF-3 expression by B-Raf mediates the neuroprotective action of GW5074. J.Neurochem. *105* 1300. PMID: 18194435.

Caution - Not Fully Tested • Research Use Only • Not For Human or Veterinary Use